Bellicum Pharmaceuticals Inc. (BLCM)

Name: Bellicum Pharmaceuticals Inc. (BLCM) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Bellicum Pharmaceuticals Inc. (BLCM)

Stock Card

$0.07

$-0.13 (-62.65%)

As on 04-Mar-2024 14:59EDT

Market cap

$1 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

P/B Ratio

40.3

Div. Yield

0 %

Bellicum Pharmaceuticals (BLCM) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.07 High: 0.09

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-22 Mln
ROE

-1.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1.9
Debt to Equity

0
Book Value

$--
EPS

$-1.6
Face value

--
Shares outstanding

9,716,930

10 Years Aggregate

CFO

$-497.20 Mln

EBITDA

$-474.57 Mln

Net Profit

$-583.21 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Bellicum Pharmaceuticals (BLCM)	--	--	-73.3	-91.2	-73.1	-70.4	--
BSE Sensex^*	-9.6	-2.0	3.1	-4.7	5.4	6.0	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Mar-2024 | *As on 02-Sep-2026 | #As on 26-Oct-2023

Company	2022	2021	2020	2019	2018	2017	2016
Bellicum Pharmaceuticals (BLCM)	-51.7	-57.8	-72.6	-55.8	-65.1	-38.3	-32.8
S&P Small-Cap 600	-17.4	25.3	9.6	20.9	-9.7	11.7	24.7
BSE Sensex	4.4	22.0	15.8	14.4	5.9	27.9	1.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Bellicum Pharmaceuticals (BLCM)

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's... clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas. Read more

Chief Executive Officer

Mr. David M. Maggio
Chief Executive Officer

Mr. David M. Maggio
Headquarters

Houston, TX
Website

https://www.bellicum.com

FAQs for Bellicum Pharmaceuticals (BLCM)

What is the current share price of Bellicum Pharmaceuticals Inc (BLCM) Today?

The share price of Bellicum Pharmaceuticals Inc (BLCM) is $0.07 (NASDAQ) as of 04-Mar-2024 14:59 EDT. Bellicum Pharmaceuticals Inc (BLCM) has given a return of -73.13% in the last 3 years.

What is the current PB & PE ratio of Bellicum Pharmaceuticals Inc (BLCM)?

Since, TTM earnings of Bellicum Pharmaceuticals Inc (BLCM) is negative, P/E ratio is not available.
The P/B ratio of Bellicum Pharmaceuticals Inc (BLCM) is 40.34 times as on 04-Mar-2024, a 679 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2022	-0.17	2.06
2021	-2.46	0.97
2020	-3.25	-11.22
2019	-0.05	-0.25
2018	-0.13	0.18

What is the 52 Week High and Low of Bellicum Pharmaceuticals Inc (BLCM)?

The 52-week high and low of Bellicum Pharmaceuticals Inc (BLCM) are Rs -- and Rs -- as of 02-Sep-2026.

What is the market cap of Bellicum Pharmaceuticals Inc (BLCM)?

Bellicum Pharmaceuticals Inc (BLCM) has a market capitalisation of $ 1 Mln as on 04-Mar-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Bellicum Pharmaceuticals Inc (BLCM)?

Before investing in Bellicum Pharmaceuticals Inc (BLCM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.